Tiejun Yin
Overview
Explore the profile of Tiejun Yin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao L, Zhou X, Li H, Yin T, Jiang Y
J Thorac Dis
. 2024 Feb;
16(1):507-515.
PMID: 38410565
Background: Immunotherapy has been widely used to treat non-small cell lung cancer (NSCLC) but is only effective in 20% of patients. Cyclin-dependent kinase inhibitor 2A () is an important tumor...
2.
Wen S, Huang X, Xiong L, Zeng H, Wu S, An K, et al.
Mol Cell Biochem
. 2024 Feb;
479(12):3341-3354.
PMID: 38341833
Background: WD repeat domain 12 (WDR12) plays a crucial role in the ribosome biogenesis pathway. However, its biological function in colorectal cancer (CRC) remains poorly understood. Therefore, this study aims...
3.
Liang Y, Hu L, Wu H, Yin T, Zhang J
Front Oncol
. 2024 Feb;
14:1292319.
PMID: 38327739
Background: Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver malignancy with a steadily increasing incidence worldwide. ICC has insidious onset, rapid progression, and poor prognosis. More multidisciplinary clinical...
4.
Wu S, Wen S, An K, Xiong L, Zeng H, Niu Y, et al.
Front Microbiol
. 2023 Dec;
14:1281451.
PMID: 38088976
Background: Pancreatic cancer (PC) is one of the most lethal malignancies of the digestive system and is expected to be the second leading cause of cancer-related death in the United...
5.
Jiang Y, Zhang J, Feng J, Lu Y, Fan Y, Cheng L, et al.
J Genet Genomics
. 2021 Aug;
48(7):656-659.
PMID: 34366271
No abstract available.
6.
Jiang Y, Zhang J, Jiang X, Cheng L, Liao X, Li Y, et al.
Ann Palliat Med
. 2021 Feb;
10(6):7051-7056.
PMID: 33548986
Tyrosine kinase inhibitor (TKI) has greatly improved the survival of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-TKI sensitive mutations. However, TKI resistance constantly occur, although multiple...
7.
Hu L, Zhang P, Mei Q, Sun W, Zhou L, Yin T
BMC Cancer
. 2020 May;
20(1):424.
PMID: 32408907
Background: The CSC (cancer stem cell) markers often indicate poor prognosis and more cell invasion or migration of cancer patients. Podoplanin was assumed as a candidate CSC marker and predict...
8.
Zhang J, Liao X, Feng J, Yin T, Liang Y
Oncol Lett
. 2019 Oct;
18(5):4947-4955.
PMID: 31612006
Predicting the risk of severe adverse reactions to chemotherapy is of great clinical significance for proper selection of effective and safe treatment for elderly cancer patients. The present study aimed...
9.
Yin T, Jiang Y
Medicine (Baltimore)
. 2018 Oct;
97(41):e12600.
PMID: 30313047
Rationale: Primary seminal vesicle adenocarcinoma (PSVA) is an extremely rare malignancy that should be carefully differentiated from cancer originating in the prostate, colon or bladder. Without standard guidelines, radical resection...
10.
Pei X, Liu Y, Sun L, Zhang J, Fang Y, Liao X, et al.
Clin Colorectal Cancer
. 2016 May;
15(4):e149-e156.
PMID: 27155750
Introduction: The aim of this study was to evaluate the efficacy and toxicity of molecular targeted agents plus chemotherapy compared with chemotherapy alone as second-line therapy for patients with metastatic...